|
| Press Releases |
|
 |
|
| Thursday, May 20, 2021 |
|
|
Eisai to Present Data on Oncology Pipeline and Products at ASCO Annual Meeting |
| Eisai Co., Ltd. announced today that the latest data regarding its oncology pipeline and products including in-house discovered lenvatinib mesylate and eribulin mesylate will be presented at the American Society of Clinical Oncology (2021 ASCO Annual Meeting*), to be held virtually from June 4 to 8, 2021. more info >> |
|
| Wednesday, May 19, 2021 |
|
|
Anticancer Agent "Remitoro Intravenous Drip Infusion 300 microgram" (Denileukin Diftitox (Genetical Recombination)) Launched in Japan |
| Eisai Co., Ltd. announced today that it has launched the anticancer agent ?Remitoro? for Intravenous Drip Infusion 300 microgram (Denileukin Diftitox (Genetical Recombination)) with the indications of relapsed or refractory Peripheral T-cell Lymphoma (PTCL) and relapsed or refractory Cutaneous T-cell Lymphoma (CTCL), in Japan. more info >> |
|
| Friday, May 14, 2021 |
|
|
Eisai and National Cancer Center Commence Joint Research and Development Project |
| Eisai Co., Ltd. and the National Cancer Center Japan announced today that both parties have entered into a joint research and development (R&D) agreement concerning "Basic research on the drug discovery and development to accelerate development of anticancer drugs in treatment of patients with rare cancers and refractory cancers", and that research activities have commenced. more info >> |
|
| Tuesday, May 11, 2021 |
|
|
Eisai's Statement of Commitment for Carbon Neutrality by 2040 |
| Eisai Co., Ltd. announced today that it has pledged to reduce greenhouse gas (GHG) emission which causes global warming, with an aim to achieve carbon neutral, and has set its new medium- to long-term target for achieving the goals. more info >> |
|
| Friday, May 7, 2021 |
|
|
Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Receive Priority Review From FDA for LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Applications |
| Eisai Co., Ltd.and Merck & Co., Inc., Kenilworth, N.J., U.S.A. today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review for applications seeking two new approvals for the combination of LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, plus KEYTRUDA, the anti-PD-1 therapy from Merck & Co., Inc., Kenilworth, N.J., U.S.A. more info >> |
|
| Wednesday, April 28, 2021 |
|
|
RESONA and Eisai Enter Into Business Alliance Aiming to Support People Living with Dementia and to Prevent Dementia in Saitama Prefecture, Japan |
| Saitama Resona Bank, Limited, a corporation of the Resona Group, and Eisai Co., Ltd. announced today that both parties have entered into a business alliance agreement for building an ecosystem. more info >> |
|
| Friday, April 23, 2021 |
|
|
Eisai: Application Submitted for Additional Indication of Anti Cancer Agent Lenvima in Combination With Keytruda as a Treatment for Advanced Uterine Body Cancer in Japan |
| Eisai Co., Ltd. and MSD K.K. announced today an application submission in Japan for the additional indication of Eisai's in-house discovered and developed multiple receptor tyrosine kinase inhibitor, LENVIMA. more info >> |
|
|
Eisai: Gilead Sciences Submits New Drug Application in Japan for Filgotinib for the Treatment of Ulcerative Colitis with an Inadequate Response to Conventional Therapies |
| Gilead Sciences K.K. and Eisai Co., Ltd. today announced that Gilead submitted an application to Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for approval of filgotinib for an additional indication to treat patients with moderately to severely active ulcerative colitis. more info >> |
|
|
Notice Regarding Biogen's Disclosure About the Submission of Marketing Authorization Applications in Brazil, Canada, Australia, and Switzerland for Aducanumab for Alzheimer's Disease |
| Eisai Co., Ltd. announced today that Biogen has disclosed, in its Q1 2021 Earnings Press Release issued on April 22, its current submission status of the Marketing Authorization Applications (MAA) for aducanumab. more info >> |
|
| Tuesday, April 20, 2021 |
|
|
Eisai: 18-Month, Pre-Specified Analysis Showing Consistent Reduction in Clinical Outcome Measures from a Lecanemab (BAN2401) Phase 2b Clinical Trial in Early Alzheimer's Disease |
| Eisai Co., Ltd. and Biogen Inc. today announced the publication of an article, A Randomized, Double-Blind Phase 2b Proof of Concept Clinical Trial in Early Alzheimer's Disease with Lecanemab, an Anti-Abeta Protofibril Antibody, in the peer-reviewed journal Alzheimer's Research and Therapy. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
CALB (3931.HK) Included in the Hang Seng Composite Index
Feb 23, 2025 21:59 HKT/SGT
|
|
|
Four HK designer labels shine at London Fashion Week
Feb 22, 2025 22:56 HKT/SGT
|
|
|
Dollamur Announces United World Wrestling Approval Through 2028
Feb 22, 2025 22:54 HKT/SGT
|
|
|
Yashaa Global Capital Secures Financial Services Permission to Establish a Global Sports VC Fund
Feb 22, 2025 20:11 HKT/SGT
|
|
|
AsiaMedic and Sunway launch new Medical Diagnostic Imaging Centre in Novena 
Feb 22, 2025 18:00 HKT/SGT
|
|
|
Soligenix's Leadership Aims to Drive Growth in Rare Disease Markets in 2025 and 2026
Feb 22, 2025 4:50 JST
|
|
|
Alexis Mc Allister Announces as Jeton's Latest Brand Ambassador
Feb 21, 2025 23:00 HKT/SGT
|
|
|
NaaS Technology Launches $10 Million Share Repurchase Plan Boosting Market Confidence
Feb 21, 2025 21:09 HKT/SGT
|
|
|
Honda Receives Highest Ranking of 3 Stars as Part of FIA Road Safety Index, Tool for Organizations and Companies to Measure Their Road Safety Footprint
Feb 21, 2025 19:40 JST
|
|
|
Carl Zeiss Honors EuroEyes International for Exceptional Milestone in AT LISA(R) Trifocal Lens Implantations
Feb 21, 2025 18:29 HKT/SGT
|
|
|
Honda Partners with United Nations Road Safety Fund (UNRSF) to Work Toward Reduction of Fatalities from Traffic Collisions
Feb 21, 2025 19:11 JST
|
|
|
Mitsubishi Logistics Corporation, Mitsubishi Corporation, and Yourstand Inc. Advancing Completely CO2-Free Electrification of Pharmaceutical Transportation
Feb 21, 2025 15:01 JST
|
|
|
NEC Innovation Challenge awards Canada's Prevu3D Inc. with the NEC Award and NOFF Award
Feb 21, 2025 14:39 JST
|
|
|
NEC Develops Near Real-time RIC for High Performance 5G vRAN
Feb 21, 2025 12:00 JST
|
|
|
Igloo kicks off 2025 with Multi-market Partnership Wins and Chief Distribution Officer Appointment
Feb 21, 2025 09:00 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
